Longeveron
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1951 NW 7th Ave Ste 520, Miami, Florida,...Phone Number
(844) 470-2550Website
www.longeveron.comRevenue
<$5 MillionStock Symbol
LGVNIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
1
1
1
1
1
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Explore more
Longeveron Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Longeveron your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Longeveron is spiking on competitors!
Click to see if Longeveron had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Longeveron
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Longeveron has new funding data
Product Launch: Get notified when Longeveron launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Longeveron, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Longeveron recently announced quarterly report
Check if Longeveron has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Longeveron
Find 3 more new buyers
Compare Similar Companies to Longeveron
Compare insights from companies similar to Longeveron, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Longeveron is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Longeveron is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Longeveron.
Longeveron financials insights
Gather financial insights about Longeveron, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2021
Share Placement
$20M
2024
Private Equity
$6.4M
Unspecified
$4.4M
2026
Stock/Share Issuance
$15.9M
Longeveron Tech Stack
A closer look at the technologies used by Longeveron
See more technologies
Most Recent Scoops
Promotion
Executive Move
Executive Moves, Promotion
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Stake & Stock Ownership, Finance, Tax
Person-Based
Stake & Stock Ownership, Finance, Tax
Left Company
Executive Move
Executive Moves, Left Company
Longeveron News & Media
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Longeveron has appointed Nirav Jhaveri, CFA, as Chief Financial Officer. He has over 25 years of experience in capital markets and corporate finance.Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript
Longeveron Inc. (LGVN) Q2 2026 Earnings Call August 12, 2026 4:30 PM EDTCompany ParticipantsDerek ColeStephen Willard - CEO & DirectorNataliya Agafonova...Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
Longeveron reports 2026 Q2 financial results. On track for Sept 2026 results for Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS).Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
Longeveron selected from over 600 worldwide applicants to advance to the final phase of the XPRIZE Healthspan competition as a Milestone 2 Awardee.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Longeveron
Sign Up For FreeTo access detailed company insights
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is cond... Read More
